8-K: Notable Labs Receives FDA Clearance for Volasertib Phase 2 Trial, Dosing Plan Agreed

Notable Labs has received FDA clearance and agreed on a dosing plan for its Phase 2 clinical trial of volasertib for relapsed refractory acute myeloid leukemia, paving the way for patient enrollment.

Summary

• Notable Labs has announced that it has received FDA clearance to proceed with its Phase 2 clinical trial of volasertib.
• The company has also reached an agreement with the FDA on the dosing plan for the trial.
• The Phase 2 study will evaluate volasertib in combination with decitabine for patients with relapsed refractory acute myeloid leukemia (R/R AML).
• The trial will begin with a dose optimization lead-in phase, followed by enrollment of patients predicted to respond to volasertib based on Notable's Predictive Medicine Platform (PMP).
• Notable expects to have initial data from the dose optimization phase in the fourth quarter of 2024 and initial efficacy results in the first half of 2025.

Sentiment

Score: 8

Explanation: The document conveys a positive sentiment due to the FDA clearance and agreement on the dosing plan, which are significant milestones for the company. The use of a predictive platform and the potential for a new treatment option for AML also contribute to the positive outlook.

Positives

• FDA clearance and agreement on the dosing plan are significant milestones for the volasertib program.
• The use of the Predictive Medicine Platform (PMP) aims to improve patient outcomes by selecting likely responders.
• The trial design incorporates learnings from previous studies and the drug's originator, Boehringer Ingelheim.
• The study has the potential to provide a new treatment option for patients with R/R AML, an area of unmet medical need.

Risks

• The company faces risks associated with clinical development and regulatory approval of product candidates.
• There are risks related to the company's ability to obtain sufficient additional capital to continue to advance its programs.
• There are uncertainties in obtaining successful clinical results and unexpected costs may arise.
• The company faces risks related to the failure to realize any value from product candidates.
• The company's future financial and operating results are uncertain, including its ability to become profitable.
• The company's ability to retain key personnel is a risk.
• The company faces risks related to the Israel-Hamas war.
• The company faces risks related to obtaining regulatory approval for any of its drug candidates.

Future Outlook

Notable expects to initiate patient enrollment in the Phase 2 study in the coming months, with initial data from the dose optimization lead-in expected in Q4 2024 and initial efficacy results expected in H1 2025.

Management Comments

• Thomas Bock, M.D., Chief Executive Officer of Notable, stated that receiving FDA clearance and agreement on a Phase 2 dosing plan positions the company to move forward to activate study sites.
• Glenn Michelson, M.D., Chief Medical Officer of Notable, commented that the study design and enrollment strategy for volasertib has been informed by robust clinical validation trials and learnings from the agents originator.
• Amer Zeidan, MBBS, Associate Professor of Medicine, shared his excitement about the potential of volasertib in combination with Notable's platform and the enhanced trial design.

Industry Context

This announcement is significant in the context of the oncology industry, where there is a high unmet need for effective treatments for relapsed refractory AML. The use of a predictive platform to identify likely responders is an innovative approach that could improve clinical trial outcomes and patient care.

Comparison to Industry Standards

• The use of a predictive platform like Notable's PMP is not yet a standard practice in clinical trials, giving Notable a potential competitive advantage.
• Other companies developing AML treatments include AbbVie with Venclexta and Agios Pharmaceuticals with Tibsovo, but Notable's approach of using a predictive platform is a differentiator.
• Boehringer Ingelheim's previous Phase 3 study of volasertib provides a benchmark, and Notable is leveraging the learnings from that study to improve its Phase 2 trial design.

Related Party Transactions

• Amer Zeidan declared consulting fees from Notable.

Stakeholder Impact

• Shareholders will be positively impacted by the progress of the volasertib program.
• Patients with R/R AML may benefit from a new treatment option.
• The healthcare community may see a positive impact from the advancement of predictive medicine.

Next Steps

• Notable intends to initiate enrollment in the Phase 2 study for volasertib in the coming months.
• The company expects to have initial data from the dose optimization lead-in during the fourth quarter of 2024.
• Notable plans to initiate selective enrollment of PMP-predicted responders after the dose optimization phase.
• The company expects to start reporting initial efficacy results during H1 2025.

Key Dates

Keywords

volasertib, acute myeloid leukemia, AML, FDA clearance, Phase 2 clinical trial, Predictive Medicine Platform, PMP, oncology, cancer therapy, clinical development